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During periods of heavy exercise training and competition, lipid, protein, and nucleic 
molecules can become damaged due to an overproduction of reactive oxygen and 
nitrogen species (RONS) within the exercising organism. As antioxidants can prevent 
and delay cellular oxidative damage through removing, deactivating, and preventing 
the formation of RONS, supplementation with exogenous antioxidant compounds has 
become a commercialized nutritional strategy commonly adopted by recreationally 
active individuals and athletes. The following review is written as a critical appraisal of 
the current literature surrounding astaxanthin and its potential application as a dietary 
supplement in exercising humans. Astaxanthin is a lipid-soluble antioxidant carotenoid 
available to supplement through the intake of Haematococcus pluvialis-derived antiox-
idant products. Based upon in vitro and in vivo research conducted in mice exercise 
models, evidence would suggest that astaxanthin supplementation could potentially 
improve indices of exercise metabolism, performance, and recovery because of its 
potent antioxidant capacity. In exercising humans, however, these observations have yet 
to be consistently realized, with equivocal data reported. Implicated, in part, by the scar-
city of well-controlled, scientifically rigorous research, future investigation is necessary to 
enable a more robust conclusion in regard to the efficacy of astaxanthin supplementation 
and its potential role in substrate utilization, endurance performance, and acute recovery 
in exercising humans.
Keywords: antioxidants, carotenoids, Haematococcus pluvialis, oxidative stress, inflammation, delayed onset 
muscle soreness, fat oxidation, endurance exercise
iNTRODUCTiON
Reactive oxygen and nitrogen species (RONS) produced during exercise are recognized as fun-
damental stressors that can promote improvements in athletic performance and overall health 
(1–3). To ensure that improvements are sustained, recreationally active individuals and athletes 
are required to manipulate the volume, intensity and frequency of each exercise bout over time (1). 
During periods of heavy exercise training, a vast system of interrelated endogenous antioxidant 
compounds (i.e., superoxide dismutase, catalase, glutathione peroxidase) work together to ensure 
RONS production does not become detrimental (4). Multifaceted in its function, this system can 
prevent and delay the oxidation of biomolecules through removing, deactivating and preventing 
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the formation of RONS (5, 6). If exercise training becomes 
too vigorous, however, an excessive production of RONS can 
overwhelm the endogenous antioxidant defense system, caus-
ing a state of oxidative stress (7). Consequently, lipid, protein 
and nucleic molecules may become damaged, with potentially 
detrimental impacts on normal physiological function (8, 9). 
The intake/ingestion of exogenous antioxidants has, therefore, 
become common practice in both recreationally active and 
athletic populations (9). As essential non-enzymatic molecules, 
exogenous antioxidants have the potential to supplement the 
endogenous antioxidant defense system if adequately sourced 
from the diet (10). An example of a potent antioxidant that can be 
sourced through either dietary intake or supplementation is the 
xanthophyll carotenoid, astaxanthin. Previously, astaxanthin has 
been suggested to enhance exercise metabolism, performance 
and recovery as a result of its potent antioxidant capacity (11–15). 
Evidence to support this notion has been predominantly derived 
from studies using in vitro and in vivo animal models (11–13, 
15). The focus of the following review is to, therefore, critically 
appraise the current literature surrounding astaxanthin and its 
potential application as a dietary supplement within exercising 
humans. Underlying mechanistic factors pertaining to exercise 
metabolism, performance and recovery will also be considered 
alongside the identification of present and future areas of research 
focus.
ASTAXANTHiN
Astaxanthin (3,3′-dihydroxy-β, β′-carotene-4,4′-dione) is a 
naturally occurring carotenoid found in marine species, such 
as microalgae, crustacea, fish and some birds (16, 17). Utilized 
in aquaculture, astaxanthin provides the characteristic reddish 
pigment to farm-raised salmon tissue (18). Following the initial 
work of Kurashige et al. (19) and Miki (20), however, an alterna-
tive use for astaxanthin as a potent antioxidant compound in both 
in vitro and in vivo systems has been suggested. As it is oxygenated 
(C40H52O4), astaxanthin is classified as part of the xanthophyll sub-
species of the carotenoid family (21), with its potency seemingly 
underpinned by its structure at a molecular level (16, 17, 20, 22). 
With a molecular mass of 596.84 g·mol−1, astaxanthin contains 
two β-ionone ring systems within its structure that are linked by 
a polyene chain and contain the oxygenated keto and hydroxyl 
moieties (21). The presence of the polyene chain alongside each 
moiety enables astaxanthin to exert multiple antioxidant func-
tions, namely in the scavenging and quenching of RONS within 
the phospholipid membrane as well as at the surface (20, 22).
Sources of Astaxanthin
As the human organism is unable to synthesize astaxanthin natu-
rally, its uptake is dependent upon the dietary intake of foods, 
such as salmon, lobster, shrimp and crab (21). Whilst current 
data regarding the dietary intake of astaxanthin are insufficient, 
it is estimated that more than 70% of salmon production world-
wide is farm-raised where astaxanthin is utilized as a feeding 
additive (21). If it is assumed that all dietary sources of seafood 
are obtained from aquaculture, it is estimated that the average 
European adult would consume between 0.8 and 2.0  mg·day−1 
astaxanthin, with the higher percentile not expected to exceed 
intakes of 4.1 mg·day−1 (23). Alternatively, the intake of astaxan-
thin is possible through regular dietary supplementation, with 
a typical intake of 4 mg·day−1 astaxanthin recommended across 
several brands of commercially produced astaxanthin products 
(24). Existing as three separate stereoisomers [(3S, 3′S), (3R, 
3′R), and (3R, 3′S)] (25), the commercial applications of astax-
anthin range from daily capsules and soft gels to energy drinks 
and powders (18). Although the production of astaxanthin for 
aquacultural purposes can be sourced from a range of synthetic 
and natural sources, the only form currently commissioned for 
direct human consumption as a commercial product is the (3S, 
3′S)-isomer (21, 25). As a result, recent endeavors have been 
made to improve the production of astaxanthin from natural 
sources, such as Haematococcus pluvialis, to ensure that demands 
for human applications can be achieved (18).
Bioavailability of Astaxanthin
Primitive data are available from research that has quantified 
the uptake and elimination kinetics of astaxanthin in the plasma 
via high-performance liquid chromatography (26–29). This 
method of analysis was utilized by Rüfer et al. (29) during the 
investigation of 28 healthy males over a 4-week period. Prior to 
study onset, astaxanthin concentrations were quantified as non-
detectable, following which two randomized groups (n = 14 each 
group) consumed either 250 g of wild or aquacultured salmon 
daily, to obtain ~1.25 mg·day−1 astaxanthin (5 µg astaxanthin·g−1 
salmon flesh). Following 6  days of consumption, astaxanthin 
concentrations reached a plateau of 33.7 ± 16.2 nmol·L−1 (wild 
salmon) and 52.4  ±  16.2  nmol·L−1 (aquacultured salmon), 
respectively, with concentrations reported to not significantly 
change for the remainder of the protocol (29). It therefore 
appears that when the intake of astaxanthin is chronic, maximal 
concentrations can be achieved and maintained within the first 
week of intake, even when astaxanthin is obtained from differ-
ent sources. This data, however, is collated from one study only, 
where astaxanthin was consumed as part of the diet, requiring 
a daily intake of 250  g salmon (29). Future research should, 
therefore, aim to clarify the bioavailability of astaxanthin from 
a variety of different sources, including supplementation, with 
information regarding the elimination kinetics also of impor-
tance to understand how the availability of astaxanthin may 
diminish over time.
Currently, the European Food Safety Authority (EFSA) advise 
an acceptable daily intake (ADI) of 0.034  mg·kg−1·day−1 astax-
anthin (2.38 mg·day−1 in a 70-kg human) (24, 30). Despite this, 
pharmacokinetic data are available from studies that have issued 
acute doses of 40 and 100  mg, respectively (26–28). Following 
the ingestion of an acute H. pluvialis-derived 40  mg capsule, 
maximal plasma concentrations of 55.2 ±  15.0  µg·L−1 astaxan-
thin were recorded in eight healthy male participants (27). In 
the same study, uptake was significantly enhanced if astaxanthin 
was ingested as one of three lipid-based formulations (n = 8 each 
group), with maximal plasma concentrations in the range of 
90.1 and 191.5 µg·L−1 reported (27). As a result, it is advised that 
astaxanthin should be consumed alongside the intake of dietary 
fats to ensure uptake can be optimized (31). In comparison, 
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increased maximal concentrations of 1.3  ±  0.1  mg·L−1 and 
0.28 ± 0.12 mg·L−1 are reported in the plasma following an acute 
intake of 100 mg astaxanthin (26, 28). Although a high level of 
variance exists between the two studies, this may be explained 
by the low sample sizes (n =  3 each study), which should be 
addressed in future research (26, 28).
Additional information is also available regarding the phar-
macokinetics of astaxanthin following acute supplementation 
regimes. Indeed, maximal blood astaxanthin concentration is 
observed between 8 and 10  h following the intake of 40  mg 
astaxanthin (n =  32) (27), with similar times of 6.7 ±  1.2  h 
(n =  3) and 11.5  h (n =  3) also observed following doses of 
100  mg (26, 28). Furthermore, a half-life of 15.9 ±  5.3  h is 
reported following a 40 mg dose (27), with half-lives of 21 ± 11 
and 52 ± 40 h reported following the intake of a 100 mg dose 
(26, 28). It therefore appears that the concentration–time 
profile of astaxanthin is monophasic following ingestion and 
can be described as a one-compartment model. Future research 
should seek to replicate these findings in doses equivalent 
to those advocated by the EFSA (0.034  mg·kg−1), as well as 
those available in commercial astaxanthin products (4  mg). 
In doing so, optimal dosing strategies can be developed and 
subsequently implemented for both chronic and acute methods 
of administration.
Mechanism of Action
In comparison to other popular phytochemicals, astaxanthin 
has previously been reported to possess a significantly greater 
antioxidant function (19, 20, 32), with its antioxidant activities 
quantified as 10-fold greater than other carotenoids, such as 
β-carotene, and 100-fold greater than α-tocopherol (vitamin E) 
(20). In particular, astaxanthin seemingly holds an affinity for 
singlet oxygen and peroxyl radical intermediates (20–22, 32). 
Through a process of energy transfer, for example, astaxan-
thin is able to quench singlet oxygen, yielding ground state 
oxygen alongside astaxanthin in a triplet-excited state (21). 
As a carotenoid, astaxanthin is then able to dissipate this energy 
by interacting with surrounding solvent, returning back to the 
ground state structurally intact, ready to participate in further 
quenching cycles (21, 33). Additionally, astaxanthin is also able 
to scavenge and thus deactivate peroxyl radical intermediates, 
a function likely dependent upon the formation of resonance 
stabilized, carbon-centered radical adducts (21, 33). As such, an 
ability for astaxanthin to extensively protect lipid-rich structures 
against peroxidation during periods of oxidative stress has been 
suggested (20, 22, 34, 35).
Research utilizing animal models have also identified a 
potential for astaxanthin to indirectly modulate the endogenous 
antioxidant defense system through interacting with redox 
sensitive transcription factors, such as nuclear factor erythroid 
2-related factor 2 (Nrf2) (36, 37). At rest, Nrf2 is sequestered 
in the cytosol by Kelch-like ECH-associated protein 1 (Keap1); 
however, during periods of oxidative stress, modifications to 
cysteine residues on Keap1 cause Nrf2 to be released and trans-
located to nucleus where it binds to the antioxidant response 
element (ARE) (38, 39). Once activated, the Nrf2–ARE signaling 
pathway initiates the transcription of several cytoprotective genes 
and enzymes capable of upregulating the endogenous antioxidant 
response to an oxidative stressor, potentially implicating Nrf2 in 
the beneficial effects of exercise (39). Similarly, phytochemicals 
can also stimulate the activation of the Nrf2–ARE pathway, a 
process which may occur through the modification of different 
cysteine residues to those targeted through exercise, suggesting 
a potential synergism between exercise and phytochemicals in 
the upregulation of antioxidant defense (39). Although a specific 
mechanism of action has yet to be elucidated, research con-
ducted in animal models report increases in Nrf2 expression, 
alongside the upregulation of endogenous antioxidant enzymes, 
including superoxide dismutase, catalase and glutathione 
peroxidase, following astaxanthin administration (36, 37, 40). 
As key components of the endogenous antioxidant defense 
system (41), it is plausible that astaxanthin could activate 
endogenous antioxidant defense pathways upon administration. 
Future research is therefore required to investigate this mecha-
nism further, including the interaction between astaxanthin and 
Nrf2 in exercising humans.
Safety of Astaxanthin Supplementation
In 2014, the EFSA Panel on Additives and Products or 
Substances used in Animal Feed (FEEDAP) advocated an ADI 
of 0.034  mg·kg−1·day−1 astaxanthin (2.38  mg·day−1 in a 70  kg 
human) based upon research previously conducted in rats (30). 
This was later reiterated by an EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA), where it was concluded that 
the safety of 4 mg·day−1 astaxanthin (~0.06 mg·kg−1·day−1) had 
yet to be fully established (24). In contrast, no adverse effects 
were reported in blood pressure or biochemical parameters, 
including a metabolic panel and cell blood count, in 19 healthy 
participants supplementing with 6  mg·day−1 astaxanthin for 
8  weeks (42). Similarly, no adverse effects were also reported 
in a recent exercise study where 16 trained individuals sup-
plemented with 20  mg·day−1 astaxanthin for 4  weeks (43). 
The acute intake of 40 mg astaxanthin has also been reported 
as “well tolerated” in 32 healthy participants with only three 
mild events in the form of headaches reported in the 48 h post-
intake (27). This was, however, in response to a single dose, 
with information concerning the chronic intake of 40 mg·day−1 
not currently available in a healthy adult cohort. Nevertheless, 
the chronic intake of 16 mg·day−1 and 40 mg·day−1 astaxanthin 
has been suggested as safe in patients suffering with functional 
dyspepsia (44). One hundred and 31 patients were recruited 
and randomly assigned either 16 mg·day−1 astaxanthin (n = 43), 
40  mg·day−1 astaxanthin (n =  44), or an appearance-matched 
control (n = 44) for 4 weeks. Although 36 adverse events were 
reported during supplementation and a 4  week follow-up, 
prevalence was not significantly different between groups 
(16 mg·day−1: 15 adverse events in 10 patients vs. 40 mg·day−1: 
8 adverse events in 7 patients vs. control: 13 adverse events in 7 
patients) suggesting safety (44). As a result, it may be possible 
to advocate both acute and chronic intakes of astaxanthin that 
are considerably greater than the current ADI (~2.38 mg·day−1). 
Future research is therefore required to further elucidate the 
safety of astaxanthin so that human consumption guidelines can 
be adjusted accordingly.
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ASTAXANTHiN AND eXeRCiSe 
MeTABOLiSM
The metabolism of fat as an energy source is dependent upon 
the entry of long-chain fatty acids into the mitochondria; a pro-
cess requiring the mitochondrial carnitine palmitoyltransferase 
(CPT) complex and in particular the CPT1 regulatory enzyme 
(45). During exercise, RONS-induced oxidative damage to 
CPT1 can alter its function, attenuating the transportation of 
long-chain fatty acids and consequently limiting the ability for 
fats to be oxidized as a viable energy source (13). Due to its 
lipophilic properties, astaxanthin is known to accumulate in the 
mitochondrial membrane following consumption and provide 
a protection against RONS-induced detriments to its function 
(46, 47). It has, therefore, been hypothesized that through its 
function as an antioxidant, astaxanthin could protect CPT1 
against RONS-induced oxidative modifications, causing an 
indirect enhancement of exercising fat metabolism in the 
process (13).
Aoi et al. (13) investigated this hypothesis with the use of an 
exercising mouse-model. In comparison to the control, 4 weeks 
of astaxanthin supplementation (0.02% w·w−1 per 100 g of total 
dietary intake) enhanced the coimmunoprecipitation of fatty 
acid translocase (FAT)/CD36 and CPT1 by 14.5% (p < 0.05) due 
to a concomitant 41.4% decrease in the oxidative modification 
of CPT1 (p <  0.05). Muscle glycogen concentrations were also 
significantly greater in the astaxanthin group (2.7 ± 0.1 mg·g−1 
tissue) in comparison to the control (2.3 ± 0.1 mg·g−1 tissue) and 
plasma non-esterified fatty acid (NEFA) concentrations tended 
to be higher (astaxanthin group: 1.05 ± 0.05 mEq·L−1 vs. control 
group: 0.94 ±  0.05 mEq·L−1), suggesting a potential glycogen 
sparing effect (13). In a separate cohort of mice undertaking 
the same supplementation protocol, the respiratory exchange 
ratio (RER) was significantly lower from 20 min onward during 
a 60  min run (25  m·min−1), with corresponding measures of 
fat oxidation (mg·kg−1·min−1) also 21% higher (p <  0.05) and 
carbohydrate oxidation (mg·kg−1·min−1) 12% lower (p <  0.05) 
in comparison to the control (13). As a result, it was concluded 
that the antioxidant potential of astaxanthin is able to indirectly 
enhance the utilization of fats during exercise through increasing 
the intercalation of FAT/CD36 and CPT1 on the mitochondrial 
membrane (13). Similar findings are also reported in a swim-
ming mouse-model (12). On completion of a 15  min swim 
against an additional 5% body mass, mice supplemented with 6 
and 30 mg·kg−1 astaxanthin for 3 weeks had significantly greater 
plasma glucose concentrations (6  mg·kg−1: 124  mg·dL−1 vs. 
30 mg·kg−1: 135 mg·dL−1 vs. control: 104 mg·dL−1), with plasma 
NEFA also significantly elevated throughout exercise in the 
30 mg·kg−1 astaxanthin group. Muscle glycogen concentrations 
were also significantly greater post-exercise following 5 weeks of 
supplementation with 6 and 30 mg·kg−1 astaxanthin (6 mg·kg−1 
group: 4.0  mg·g−1 vs. 30  mg·kg−1 group: 4.2  mg·g−1 vs. control 
group: 3.4 mg·g−1), with liver glycogen concentration also signifi-
cantly greater in the 30 mg·kg−1 group (30 mg·kg−1: 49.8 mg·g−1 vs. 
control: 40.7 mg·g−1). In contrast, however, a significant decrement 
in plasma NEFA concentration has been reported post-exercise 
(30 min run at 25 m·min−1) in mice supplemented with 0.02 w·w−1 
astaxanthin for 2 weeks (astaxanthin group: 905 ± 41 mEq·L−1 vs. 
control group: 1,151 ± 61 mEq·L−1) (15). Although the authors 
speculated that this resulted from an increased utilization 
within the skeletal muscle, no direct measurement was made 
(15). Furthermore, despite a tendency for plasma glucose to be 
higher post-exercise in the astaxanthin group (astaxanthin group: 
121 ± 2 mg·dL−1 vs. control group: 112 ± 3 mg·dL−1), a significant 
supplement effect was not reported, suggesting that astaxanthin 
did not exert a glycogen-sparing effect (15).
Evidence from exercising mice models would therefore sug-
gest that 3–5 weeks of astaxanthin supplementation potentially 
exerts a metabolic benefit through enhancing fat utilization and 
attenuating muscle glycogen depletion during endurance-type 
exercise (12, 13). It should, however, be noted that outcomes 
reported in an animal model are not always replicable in a 
human model (48). Interestingly, a similar metabolic effect has 
yet to be replicated within an exercising human cohort (14, 
43). Four weeks of 4 mg·day−1 astaxanthin supplementation, for 
example, did not influence parameters of substrate metabolism 
(such as RER, carbohydrate and fat oxidation rates, and plasma 
glucose and NEFA concentrations) obtained during 2  h of 
submaximal cycling (5% below lactate threshold) in amateur 
endurance-trained males (n = 14; V˙O2max ≥50 mL·kg−1·min−1) 
(14). The 4 mg·day−1 dose issued, however, was trivial in com-
parison to the 6–30  mg·kg−1 doses that have been previously 
prescribed in a mouse-model (12). To elicit a similar metabolic 
modulation as previously reported in a mouse-model, it was 
therefore hypothesized that a dose greater than 4  mg·day−1 
would be required in an exercising human cohort (43). As a 
result, Res et al. (43) recruited trained male cyclists or triathletes 
(V˙O2peak: 60 ± 1 mL·kg−1·min−1) to a 4 week supplementation 
protocol consisting of either 20  mg·day−1 astaxanthin, or an 
appearance-matched control in a double-blind, parallel design 
(n =  16 astaxanthin group; n =  15 control group). Despite a 
fivefold increase in dose, however, measures of RER, carbo-
hydrate and fat oxidation rates, and concentrations of plasma 
glucose and free fatty acids were again not significantly affected 
during the completion of a 1 h steady-state cycle (50% Wmax) 
(43). Based upon this evidence, it would therefore appear that 
4 weeks of astaxanthin supplementation does not exert a meta-
bolic effect during endurance exercise, even at greater levels of 
intake, in exercising humans.
Res et  al. (43) also detected no measurable changes in the 
plasma concentrations of the lipid peroxide malondialdehyde 
(MDA) during exercise, suggesting an antioxidant effect of 
astaxanthin was not present. Although speculative, this observa-
tion may provide an insight as to why a metabolic effect was not 
reported in this study, with previous research suggesting that an 
indirect metabolic modulation is mediated through a protection 
of CPT1 from astaxanthin (13). The lack of a direct antioxidant 
effect and the corresponding metabolic effect, reported by Res 
et  al. (43), may be attributable to either the high training and 
fitness demographics of the participants recruited (V˙O2peak: 
60 ± 1 mL·kg−1·min−1; training frequency: >3 sessions·week−1 for 
≥2 years) or the length of the supplementation period undertaken 
within this study (43). Concentrations of MDA, for example, 
were reported to decrease significantly in sedentary individuals 
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following 20 mg·day−1 astaxanthin for both 8 (astaxanthin group: 
1.72 ± 0.28 µmol·L−1 vs. control group: 2.08 ± 0.12 µmol·L−1) and 
12  weeks (astaxanthin group: 1.42 ±  0.29  µmol·L−1 vs. control 
group: 2.00 ± 0.24 µmol·L−1), respectively (49). Likewise, 12 weeks 
of 8 mg·day−1 astaxanthin supplementation was also reported to 
attenuate markers of lipid peroxidation in healthy untrained males 
(50), suggesting that the demographics of participants may be a 
confounding variable for the antioxidant action of astaxanthin. 
Furthermore, the rate at which fat is oxidized during exercise is 
also subject to large inter-individual variations, even at the same 
absolute and relative intensities (51–53). The exercise intensity at 
which fat oxidation is maximal (FATmax) is again highly variable 
between individuals (51, 53). In 300 healthy men and women, for 
example, FATmax values in the range of 25 and 77% V˙O2max were 
reported despite an average value of 48 ±  1% V˙O2max reported 
overall (53). Consequently, if fat oxidation is measured at a 
constant steady-state intensity, the ability to determine the true 
effect of a nutritional intervention may be diminished as some 
individuals will be exercising above and others below the exer-
cise intensity at which FATmax is elicited. Future research should 
consider participant demographics, such as training status, the 
supplementation protocols administered, as well as incorporat-
ing sensitive measurements of exercising substrate utilization. 
This may include employing an experimental protocol capable 
of detecting changes in metabolism across a range of exercise 
intensities (52, 53), so that the metabolic effect of astaxanthin can 
be explored in more depth in exercising humans.
ASTAXANTHiN AND eXeRCiSe 
PeRFORMANCe
During endurance exercise, the depletion of muscle glycogen is 
commonly reported in the etiology of fatigue; as such, methods 
aimed at attenuating this depletion, may provide an ergogenic 
benefit through delaying fatigue onset (54). A metabolic mecha-
nism that could potentially convey this benefit is the utilization 
of fat as an alternative energy source to glycogen during exercise 
(45). With previous research conducted in mice illustrating such 
a metabolic effect (12, 13), a potential for astaxanthin to act as an 
ergogenic aid during the performance of endurance exercise has 
been hypothesized (12–14, 43).
Ikeuchi et al. (12) conducted a series of experiments in mice 
to investigate the ergogenic potential of astaxanthin (1.2, 6, 
or 30 mg·kg−1) on swim time to exhaustion (TTE). In the first 
experiment, mice undertook a weekly swim TTE against an addi-
tional 10% body mass over a 5 week supplementation period. In 
comparison to the control, a continuous significant improvement 
in TTE was observed from the first week onward in the mice 
supplemented with 6 (p < 0.01) and 30 mg·kg−1 (p < 0.05) astax-
anthin. After 5 weeks, this significant improvement was observed 
in a dose-dependent manner across all astaxanthin groups with 
an ergogenic benefit also reported in the 1.2 mg·kg−1 astaxanthin 
group (1.2 mg·kg−1 group: 2.27 min vs. 6 mg·kg−1 group: 3.32 min 
vs. 30 mg·kg−1 group: 5.12 min vs. control group: 1.44 min) (12). 
Similar results were also reported in a separate cohort of mice, 
as 3  weeks of 6 and 30  mg·kg−1 astaxanthin supplementation 
significantly improved swim TTE against an additional 5% body 
mass (6 mg·kg−1 group: 27.50 ± 3.04 min vs. 30 mg·kg−1 group: 
36.06 ±  4.13  min vs. control group: 19.45 ±  2.02  min) (12). 
Further support is also evident from a running mouse-model, as 
mice fed daily with 0.02 w·w−1 astaxanthin for 4 weeks were able 
to significantly enhance TTE at a running intensity of 30 m·min−1 
by 34% (67.53 ± 4.20 min) in comparison to the exercising control 
(50.40 ± 5.00 min) (13).
Based upon in  vivo work conducted in mice, it therefore 
appears that astaxanthin is able to exert an ergogenic benefit dur-
ing the performance of endurance exercise; an ability attributed 
to its aforementioned effect on substrate metabolism (12, 13). 
In humans, a similar ergogenic benefit was reported in amateur 
trained male cyclists (n = 14; V˙O2max > 50 mL·kg−1·min−1; weekly 
cycling volume > 160 km·week−1), as 4 weeks of astaxanthin sup-
plementation (4 mg·day−1) significantly improved 20 km cycling 
time trial (TT) performance when compared to baseline (baseline: 
2,387 ± 206 s vs. 4 weeks: 2,266 ± 190 s) (14). Furthermore, the 
121 s time improvement (5%) reported in the astaxanthin group 
was also significantly greater than the corresponding 18 s improve-
ment (<1%) reported in the control (baseline: 2,251 ± 260 s vs. 
4 weeks: 2,233 ± 283 s), suggesting a treatment effect was present 
(p < 0.05; effect size: 1.25) (14). In contrast, an ergogenic benefit 
was not reported during a 1 h cycling TT in well-trained male 
cyclists or triathletes (n =  31; V˙O2peak: 60 ±  1  mL·kg−1·min−1; 
training frequency: >3 sessions·week−1 for >2  years) following 
a 4 week supplementation with either 20 mg·day−1 astaxanthin 
(baseline: 60.38 ±  1.20  min vs. 4  weeks: 59.14 ±  1.21  min) or 
an appearance-matched control (baseline: 59.43  ±  1.37  min 
vs. 4 weeks: 58.57 ± 1.39 min) (43). Although there is no clear 
explanation for the disparity between the two findings, it should 
be noted that a metabolic mechanism was not reported by 
either study (14, 43). As the enhancement of fat metabolism and 
the subsequent sparing of muscle glycogen are the suggested 
mechanisms by which astaxanthin exerts its ergogenic potential, 
the absence of this effect may implicate an alternative ergogenic 
mechanism in Earnest et al. (14), or partially explain the absence 
of a performance effect in Res et al. (43). It is plausible, however, 
that the heterogeneity of the sample in Earnest et  al. (14) may 
have contributed to the disparity reported between studies with 
regards to TT performance. Participants were randomly assigned 
to each treatment group and although a full familiarization was 
completed and baseline fitness characteristics appeared to be 
similar, the SD of each 20 km TT (190–283 s) was far greater than 
the 136 s time improvement reported in the astaxanthin group. 
To ensure the reliability of the performance outcome reported, 
the retest reliability of the 20 km TT should have been reported. 
As this information is not available, it is difficult to conclude 
whether the time improvement reported in the astaxanthin 
group (5%) resulted from a significant supplement effect or the 
variation present in the study protocol. Previously, a coefficient of 
variation (CV) of 1.5% (1.1–2.1%; ±10% confidence limits) has 
been reported for the performance of a 20 km TT separated by 
4 weeks in 19 competitive level cyclists (>2 years racing experi-
ence at an A or B grade standard) (55). If a similar retest reliability 
would have been reported by Earnest et al. (14), the ergogenic 
effect of astaxanthin could have been inferred as the performance 
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improvement during the 20  km TT would have been greater 
than the CV reported. Future research should, therefore, seek to 
confirm whether an ergogenic potential of astaxanthin is present 
within an exercising human cohort, with a particular emphasis 
placed upon the reliability of testing protocols to ensure that a 
more robust conclusion can be made. In comparison to previous 
performance studies, future research should also consider imple-
menting performance tests of a longer duration (>1 h), allowing 
the ergogenic potential of astaxanthin to be investigated during 
the completion of an exercise bout that may reflect the proposed 
mechanism of action more appropriately.
ASTAXANTHiN AND eXeRCiSe 
ReCOveRY
The completion of vigorous intensity exercise training sessions 
and competitive events are known to increase numerous physi-
ological stressors, such as muscle damage, oxidative stress and 
inflammation (56). Detriments to the skeletal muscle observed 
in response to the completion of vigorous intensity exercise may, 
therefore, not only result from damage directly induced by RONS 
but also damage induced through the inflammatory cascade. If 
recovery is inadequate following exercise, it may prevent rec-
reationally active individuals and athletes from completing the 
subsequent exercise training sessions required to drive adapta-
tion and/or performance improvements. Inadequate recovery 
may also increase risks of injury, illness and overtraining (57). 
As a result, the investigation of strategies that can reduce the nega-
tive effect of exercise-induced muscle damage and/or accelerate 
the recovery process has become increasingly popular (56, 58–60).
Through its potency as an antioxidant compound, it is plausible 
to propose that astaxanthin could exert a recovery benefit through 
the inhibition of both pro-oxidant and pro-inflammatory inter-
mediates (11, 61). In vitro research has reported a dose-dependent 
inhibition of nitric oxide (NO) and intracellular RONS, as well 
as the hydrogen peroxide-induced activation of nuclear factor 
kappa B (NFκB) following 5–100 µM astaxanthin administration 
(61). Furthermore, 50  µM astaxanthin also completely inhib-
ited the stimulation of inducible nitric oxide synthase (iNOS) 
and iNOS mRNA. As iNOS is predominantly present in many 
inflammatory conditions (62), the subsequent expression of pro-
inflammatory cytokines, such as tumor necrosis factor-α (TNF-
α) and interleukin-1β (IL-1β), were also significantly suppressed 
(TNF-α: −76%; IL-1β: −46%) in comparison to the control (61). 
Investigation with in vivo mouse models also reported a similar 
effect following a lipopolysaccharide stressor, with significant 
reductions in plasma NO (−58%), TNF-α (−50%), and IL-1β 
(−57%) reported following treatment with a 40  mg·kg−1 dose 
of astaxanthin in comparison to the control (61). Although the 
work of Lee et al. (61) was not specific to the recovery response 
to exercise per  se, it displays a potential mechanism by which 
astaxanthin may promote recovery through inhibiting the oxi-
dative and inflammatory responses to a physiological stressor. 
Supportive evidence is, however, received from an exercising 
mouse model (11). Following a running TTE at an intensity of 
28 m·min−1, 3 weeks of astaxanthin supplementation (0.02 w·w−1) 
attenuated oxidative damage to lipid and nucleic acid molecules 
in the skeletal and cardiac muscle tissue. This was evidenced 
by the substantial decrease of 4-hydroxy-2-nonenal (4-HNE) 
modified protein production, as well as the significant inhibi-
tion of 8-hydroxy-2′-deoxyguanosine (8-OHdG) in the skeletal 
(−12%) and cardiac (−17%) muscle tissue, in comparison to the 
control (11). Furthermore, 24 h post-exhaustive exercise, dietary 
astaxanthin also significantly decreased the activity of myeloper-
oxidase (MPO) by 50% in the skeletal muscle tissue and 33% in 
the cardiac muscle tissue in comparison to the control, as well as 
significantly reducing creatine kinase (CK) activity in the plasma 
(astaxanthin: 2,617 U·L−1 vs. control: 3,032 U·L−1) (11). As MPO 
and CK are markers of the secondary neutrophil infiltration and 
muscle damage, this also highlights a potential for astaxanthin to 
attenuate the inflammatory muscle damage response in the days 
following exhaustive exercise.
The use of in vitro and in vivo mouse-models have, therefore, 
demonstrated an ability of astaxanthin to inhibit a series of bio-
markers linked to the onset of muscle damage, oxidative stress, 
and/or inflammation. As a result, research has subsequently 
aimed to elucidate whether astaxanthin supplementation pos-
sesses the ability to modulate the recovery response in an exercis-
ing human cohort. In a sample of 20 resistance-trained males, 
for example, recovery from a muscle damaging bout of eccentric 
exercise was quantified through perceptions of muscle soreness, 
concentrations of plasma CK and the recovery of one repetition 
maximum concentric strength, mean isometric force, and mean 
dynamic force (63). Although a significant time effect for each 
measure was present in the 96  h post-exercise, a supplement 
effect of 4 mg·day−1 astaxanthin for 3 weeks prior to exercise was 
not observed. As young, resistance-trained males were recruited, 
however, it is uncertain as to whether this outcome could be 
generalized to less trained individuals or to those participating in 
events other than high force, resistance exercise. Future research 
should, therefore, aim to address this uncertainty by recruiting 
participants with different training demographics to investigate 
whether training status can confound the efficacy of astaxanthin 
as a recovery aid post-exercise. More recently, markers of muscle 
damage and oxidative stress were measured in response to a 2 h 
bout of soccer exercise in elite youth male soccer players (n = 32; 
age: 17–18  years) following supplementation with 4  mg·day−1 
astaxanthin for 90  days during the regular competitive season 
(64). A supplement effect was not reported in exercise-induced 
changes in plasma CK and generic measures of oxidative stress 
(thiobarbituric acid-reactive substances, advanced oxidation 
protein products, superoxide anion, total antioxidant status, 
sulphydril groups, and superoxide dismutase), suggesting a 
recovery effect was not present (64). The same research group 
later conducted a similar investigation in a separate cohort of elite 
youth male soccer players (n = 40; age: 17–18 years) during the 
competitive season (65). Adherence to exercise training alone 
over the 90 day protocol was reported to significantly attenuate 
muscle damage, implicated by a reduction in both plasma CK 
(astaxanthin: −44.6%; control: −30.1%) and lactate dehydro-
genase (LDH) (astaxanthin: −27.4%; control: −18.5%) from 
baseline measures. Astaxanthin supplementation (4  mg·day−1) 
was suggested to augment these reductions further, while also 
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exerting a secondary anti-inflammatory effect through attenuat-
ing training-induced increases in serum C-reactive protein and 
total leukocyte and neutrophil counts, in comparison to the 
control (65). Caution is required however, as a significant sup-
plement effect of astaxanthin was not reported in regard to each 
of the aforementioned measures, apart from the LDH biomarker 
(p < 0.05); suggesting that astaxanthin actually had little effect. 
Furthermore, when attempting to elucidate the effect of astaxan-
thin on muscle damage and recovery responses to exercise, both 
Djordjevic et al. (64) and Baralic et al. (65) placed a heavy reliance 
upon indirect biomarkers such as CK and/or LDH obtained from 
the blood. Both CK and LDH have been reported to possess a 
large inter-individual variance and low reliability in blood 
concentrations (58), with the use of muscular force production 
purported to be a more reliable marker of skeletal muscle injury 
(58, 66). Future research should, therefore, be conducted with the 
use of suitable analytical methods so that a more comprehensive 
conclusion can be made regarding astaxanthin and the attenua-
tion of exercise-induced muscle damage in exercising humans.
CONCLUSiON
Previous research conducted in both in  vitro cell-cultures and 
in  vivo animal models provide evidence to support the use of 
astaxanthin as a dietary supplement for recreationally active 
individuals and athletes. According to these models, exercise 
metabolism, performance and recovery is improved following 
3–5  weeks of intake; with each function attributed in part to 
the potent antioxidant capacity of this xanthophyll carotenoid. 
In contrast, the current efficacy surrounding astaxanthin sup-
plementation in exercising humans is somewhat equivocal. This 
is evidenced by the limited number of well-controlled scientific 
investigations in this research area. Future research is therefore 
required with a particular emphasis placed upon scientific 
rigor and contemporary considerations of the most appropriate 
methodological and analytical strategies. Only once this has 
been achieved can a more robust conclusion be made about the 
application of astaxanthin as a dietary supplement for exercising 
humans.
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